In this episode of Behind the Insights, Jessica Probst, MPH, Principal, Real-World Evidence at OM1 and Dr. Carl Marci, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1, unpack a topic that’s made recent headlines and raised important questions for both clinicians and patients, suicidal ideation (SI) warnings on GLP-1 medications. While these labels have sparked concern, these experts will be discussing what the data has to say.

0:00 Intro

0:45 What inspired you to investigate potential ties between GLP-1 therapies and SI?

1:18 How did you identify instances of suicidal ideation in RWD?

2:08 Key findings

2:45 How should clinicians should manage care going forward?

3:08 Shaping future conversations

📩 Stay updated on future episodes:  ...